Desarrollo in vitro de la orquídea epífita Erycina hyalinobulbon (Orchidaceae), endémica de México, para promover su conservación

Background and Aims: Orchids in Mexico are mainly threatened by deforestation, changes in land use, illegal trade, deficiencies in environmental policy and legislation, and a lack of community participation in the conservation of their forests. Erycina hyalinobulbon is an endemic twig epiphyte orchid with a short life cycle and with large flowers in relation to its size, for which it has been harvested from its wild populations. The objectives of this work were to evaluate the in vitro development of E. hyalinobulbon in culture media with organic supplements, to compare sucrose vs. N’Joy Stevia® as a carbon source for its initial stages of development, and to evaluate the development of its seedlings in media enriched with plant growth regulators (PGR).Methods: For the sowing of seeds, PhytamaxTM and MS medium at 30% of its basal salts were used in combination with organic supplement (coconut milk, pineapple puree and banana puree), along with the Phy medium used as control. In order to measure the effect of sucrose vs. N´Joy Stevia® as a carbon source, these two treatments were used, with the PhytamaxTM medium. To evaluate the development of seedlings with PGR, three treatments were tested: the 100% PhytamaxTM control, 30% PhytamaxTM with 1.166 ml/l of Maxi-grow and the medium Chiu.Key results: PhytamaxTM medium added with banana promoted germination by 9.3%, being a low cost and easy production option. Ninety days after sowing, N´Joy Stevia® as a carbon source promoted germination by 8%. The best development of the seedlings was registered in the medium PhytamaxTM without PGR.Conclusions: With this study, it was possible to develop an accessible in vitro propagation system for E. hyalinobulbon, in order to sustainably manage it and favor its conservation.Antecedentes y Objetivos: Las orquídeas en México están amenazadas principalmente por deforestación, cambios de uso de suelo, comercio ilegal, carencias en la legislación y política ambiental y por una falta de participación de las comunidades para la conservación de sus bosques. Erycina hyalinobulbon es una orquídea endémica epífita de ramilla con un ciclo de vida corto y grandes flores en relación a su tamaño, por lo que ha sido extraída de sus poblaciones silvestres. Los objetivos de este trabajo fueron evaluar el desarrollo in vitro de E. hyalinobulbon en medios de cultivo con suplementos orgánicos, comparar la sacarosa vs. N´Joy Stevia® como fuente de carbono en sus primeras etapas de desarrollo y evaluar el desarrollo de sus plántulas con medios enriquecidos con reguladores de crecimiento vegetal (PGR).Métodos: Para la siembra de semillas los medios de cultivo PhytamaxTM y MS, a 30% de sus sales basales, fueron utilizados con suplementos orgánicos (leche de coco, puré de piña y puré de plátano), utilizando el medio Phy como control. Para poder medir el efecto de la sacarosa vs. N´Joy Stevia®, se utilizaron estos dos tratamientos con el medio PhytamaxTM. Para evaluar el desarrollo de plántulas con PGR, se hicieron tres tratamientos: control de PhytamaxTM 100%, PhytamaxTM 30% con 1.166 ml/l de Maxi-grow y el medio Chiu.Resultados clave: El medio PhytamaxTM adicionado con plátano promovió la germinación en 9.3%, siendo una opción de bajo costo y fácil producción. A los noventa días de efectuada la siembra, N´Joy Stevia® como fuente de carbono promovió la germinación con 8%. El mejor desarrollo de las plántulas se obtuvo en el medio PhytamaxTM sin PGR.Conclusiones: Con este estudio se logró desarrollar un sistema de propagación in vitro de E. hyalinobulbon accesible para poder manejarla sustentablemente y favorecer su conservación

GUÍA DE ATENCIÓN PSICOLÓGICA VIRTUAL PARA PERSONAS DE GRUPOS VULNERABLES EN CRISIS POR LA PANDEMIA COVID-19

La Guía de Atención Psicológica Virtual “GAPV_COVID-19” se presenta al lector como una herramienta necesaria para los profesionales de la salud y la salud mental. A pocos meses de tener frente a nosotros una problemática de salud pública mundial desatada por el brote de una nueva cepa de coronavirus, médicos, enfermeros, gobiernos y una sociedad cada vez más informada han buscado materiales médicos-psicológicos de apoyo que logren dar atención y orientación oportuna y científica a personas que no sólo padecen o padecieron la infección por la COVID-19, sino a aquellos individuos que temen infectarse o que han visto frustrados sus días debido al encierro prolongado. En México a más de siete meses del inicio de la cuarentena y de los repuntes constantes de personas infectadas por la nueva cepa, un grupo de científicos sumaron esfuerzos para crear una guía útil, práctica y de distribución electrónica gratuita para sus colegas. Su motivación es atender de manera expedita y con altos niveles de calidad los síntomas y padecimientos de las personas en el entorno actual. Estrés, depresión, ansiedad, preocupación, temor y agresividad, o apatía e incredulidad, son factores que se han acentuado a lo largo de estos meses, y que deben ser atendidos con la mayor celeridad posible. En esta Guía se demuestra que la atención y orientación a los padecimientos y síntomas que ha traído consigo el virus SARS-CoV-2, pueden ser oportunos al trabajar on line, pues los paradigmas de la atencion médica se han transformado. Ya no es necesario, en ciertas zonas del país, acudir personalmente con los profesionales de la salud. Una de las enormes ventajas de contar con dispositivos electrónicos y conexión a Internet, es el acortamiento de distancias entre pacientes y psicólogos, con lo que la atención psicológica virtual se convierte en una poderosa herramienta para el tratamiento urgente. Este esfuerzo por conectar a las personas con los profesionales de la salud mental a través de las nuevas tecnologías digitales, pronto verá sus resultados al dar tratamiento adecuado y puntual a las personas que lo soliciten.CONACyT. Apoyo 000000000312728

Investigación joven con perspectiva de género III

Actas del III Congreso Internacional de Estudios de Género, Perspectivas y Retos de Futuro: Jóvenes Investigadores (Getafe, 13 - 15 de junio de 2018) organizado por el Instituto Universitario de Estudios de Género de la Universidad Carlos III de Madrid

Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

Background: Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD). Objective: Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity. Methods: Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort from January 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL: 1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8). Results: Four hundred and thirty-nine PD patients (62.05 +/- 7.84 years old; 59% males) were included. MNCD stage was: stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advanced MNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p < 0.0001) and EUROHIS-QOL8 (p < 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages. Conclusion: Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD

The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients

Background: Mortality due to COVID-19 is high, especially in patients requiring mechanical ventilation. The purpose of the study is to investigate associations between mortality and variables measured during the first three days of mechanical ventilation in patients with COVID-19 intubated at ICU admission. Methods: Multicenter, observational, cohort study includes consecutive patients with COVID-19 admitted to 44 Spanish ICUs between February 25 and July 31, 2020, who required intubation at ICU admission and mechanical ventilation for more than three days. We collected demographic and clinical data prior to admission; information about clinical evolution at days 1 and 3 of mechanical ventilation; and outcomes. Results: Of the 2,095 patients with COVID-19 admitted to the ICU, 1,118 (53.3%) were intubated at day 1 and remained under mechanical ventilation at day three. From days 1 to 3, PaO2/FiO2 increased from 115.6 [80.0-171.2] to 180.0 [135.4-227.9] mmHg and the ventilatory ratio from 1.73 [1.33-2.25] to 1.96 [1.61-2.40]. In-hospital mortality was 38.7%. A higher increase between ICU admission and day 3 in the ventilatory ratio (OR 1.04 [CI 1.01-1.07], p = 0.030) and creatinine levels (OR 1.05 [CI 1.01-1.09], p = 0.005) and a lower increase in platelet counts (OR 0.96 [CI 0.93-1.00], p = 0.037) were independently associated with a higher risk of death. No association between mortality and the PaO2/FiO2 variation was observed (OR 0.99 [CI 0.95 to 1.02], p = 0.47). Conclusions: Higher ventilatory ratio and its increase at day 3 is associated with mortality in patients with COVID-19 receiving mechanical ventilation at ICU admission. No association was found in the PaO2/FiO2 variation

Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

© 2023 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC 4.0).Background: Recently, a novel simple classification called MNCD, based on 4 axes (Motor; Non-motor; Cognition; Dependency) and 5 stages, has been proposed to classify Parkinson's disease (PD).Objective: Our aim was to apply the MNCD classification in a cohort of PD patients for the first time and also to analyze the correlation with quality of life (QoL) and disease severity.Methods: Data from the baseline visit of PD patients recruited from 35 centers in Spain from the COPPADIS cohort fromJanuary 2016 to November 2017 were used to apply the MNCD classification. Three instruments were used to assess QoL:1) the 39-item Parkinson's disease Questionnaire [PDQ-39]); PQ-10; the EUROHIS-QOL 8-item index (EUROHIS-QOL8).Results: Four hundred and thirty-nine PD patients (62.05±7.84 years old; 59% males) were included. MNCD stage was:stage 1, 8.4% (N = 37); stage 2, 62% (N = 272); stage 3, 28.2% (N = 124); stage 4-5, 1.4% (N = 6). A more advancedMNCD stage was associated with a higher score on the PDQ39SI (p < 0.0001) and a lower score on the PQ-10 (p< 0.0001) and EUROHIS-QOL8 (p< 0.0001). In many other aspects of the disease, such as disease duration, levodopa equivalent daily dose, motor symptoms, non-motor symptoms, and autonomy for activities of daily living, an association between the stage and severity was observed, with data indicating a progressive worsening related to disease progression throughout the proposed stages.Conclusion: Staging PD according to the MNCD classification correlated with QoL and disease severity. The MNCD could be a proper tool to monitor the progression of PD.COPPADIS and the present study were developed with the help of Fundación Española de Ayuda a la Investigación en Enfermedades Neurodegenerativas y/o de Origen Genético (https://fundaciondegen.org/) and Alpha Bioresearch (www.alphabioresearch.com). Also, we received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017-2020 por el Proyecto “PROGRESION NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”) to develop a part of the COPPADIS project.Peer reviewe

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Çédille, revista de estudios franceses

Presentació

patrimonio intelectual

Actas de congresoLas VI Jornadas se realizaron con la exposición de ponencias que se incluyeron en cuatro ejes temáticos, que se desarrollaron de modo sucesivo para facilitar la asistencia, el intercambio y el debate, distribuidos en tres jornadas. Los ejes temáticos abordados fueron: 1. La enseñanza como proyecto de investigación. Recursos de enseñanza-aprendizaje como mejoras de la calidad educativa. 2. La experimentación como proyecto de investigación. Del ensayo a la aplicabilidad territorial, urbana, arquitectónica y de diseño industrial. 3. Tiempo y espacio como proyecto de investigación. Sentido, destino y usos del patrimonio construido y simbólico. 4. Idea constructiva, formulación y ejecución como proyecto de investigación. Búsqueda y elaboración de resultados que conforman los proyectos de la arquitectura y el diseño

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries